|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roy M, Luo YH, Ye M and Liu J: Nonsmall
cell lung cancer therapy: insight into multitargeted small-molecule
growth factor receptor inhibitors. Biomed Res Int.
2013:9647432013.PubMed/NCBI
|
|
5
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu CD, Altieri DC and Tanigawa N:
Expression of a novel antiapoptosis gene, survivin, correlated with
tumor cell apoptosis and p53 accumulation in gastric carcinomas.
Cancer Res. 58:1808–1812. 1998.PubMed/NCBI
|
|
7
|
Kawasaki H, Altieri DC, Lu CD, et al:
Inhibition of apoptosis by survivin predicts shorter survival rates
in colorectal cancer. Cancer Res. 58:5071–5074. 1998.PubMed/NCBI
|
|
8
|
Monzó M, Rosell R, Felip E, et al: A novel
anti-apoptosis gene: Re-expression of survivin messenger RNA as a
prognosis marker in non-small-cell lung cancers. J Clin Oncol.
17:2100–2104. 1999.PubMed/NCBI
|
|
9
|
Tanaka K, Iwamoto S, Gon G, et al:
Expression of survivin and its relationship to loss of apoptosis in
breast carcinomas. Clin Cancer Res. 6:127–134. 2000.PubMed/NCBI
|
|
10
|
Liggins C, Orlicky DJ, Bloomquist LA and
Gianani R: Developmentally regulated expression of survivin in
human pancreatic islets. Pediatr Dev Pathol. 6:392–397. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xing J, Jia CR, Wang Y, Guo J and Cai Y:
Effect of shRNA targeting survivin on ovarian cancer. J Cancer Res
Clin Oncol. 138:1221–1229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Krajewska M, Krajewski S, Banares S, et
al: Elevated expression of inhibitor of apoptosis proteins in
prostate cancer. Clin Cancer Res. 9:4914–4925. 2003.PubMed/NCBI
|
|
13
|
McKenzie JA and Grossman D: Role of the
apoptotic and mitotic regulator survivin in melanoma. Anticancer
Res. 32:397–404. 2012.PubMed/NCBI
|
|
14
|
Wheatley SP and McNeish IA: Survivin: a
protein with dual roles in mitosis and apoptosis. Int Rev Cytol.
247:35–88. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altieri DC: Survivin and IAP proteins in
cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xing J, Jia CR, Wang Y, Guo J and Cai Y:
Effect of shRNA targeting survivin on ovarian cancer. J Cancer Res
Clin Oncol. 138:1221–1229. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhen HN, Li LW, Zhang W, et al: Short
hairpin RNA targeting survivin inhibits growth and angiogenesis of
glioma U251 cells. Int J Oncol. 31:1111–1117. 2007.PubMed/NCBI
|
|
18
|
Chen XQ, Yang S, Kang MQ, et al: Survivin
expression in human lung cancer and the influence of its
downregulation on the biological behavior of human lung cancer
cells. Exp Ther Med. 3:1010–1014. 2012.PubMed/NCBI
|
|
19
|
Virrey JJ, Guan S, Li W, et al: Increased
survivin expression confers chemoresistance to tumor-associated
endothelial cells. Am J Pathol. 173:575–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang M, Mukherjee N, Bermudez RS, et al:
Adenovirus-mediated inhibition of survivin expression sensitizes
human prostate cancer cells to paclitaxel in vitro and in vivo.
Prostate. 64:293–302. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang H, Fu JH, Hu Y, et al: Influence of
siRNA targeting survivin on chemosensitivity of H460/cDDP lung
cancer cells. J Int Med Res. 36:734–747. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamazaki H, Takagi S, Hoshino Y, Hosoya K
and Okumura M: Inhibition of survivin influences the biological
activities of canine histiocytic sarcoma cell lines. PLoS One.
8:e798102013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamanaka K, Nakahara T, Yamauchi T, et al:
Antitumor activity of YM155, a selective small-molecule survivin
suppressant, alone and in combination with docetaxel in human
malignant melanoma models. Clin Cancer Res. 17:5423–5431. 2011.
View Article : Google Scholar
|
|
24
|
Chen J, Pise-Masison CA, Shih JH, et al:
Markedly additive antitumor activity with the combination of a
selective survivin suppressant YM155 and alemtuzumab in adult
T-cell leukemia. Blood. 121:2029–2037. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Asanuma K, Tsuji N, Endoh T, Yagihashi A
and Watanabe N: Survivin enhances Fas ligand expression via
up-regulation of specificity protein 1-mediated gene transcription
in colon cancer cells. J Immunol. 172:3922–3929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamamoto H, Ngan CY and Monden M: Cancer
cells survive with survivin. Cancer Sci. 99:1709–1714. 2008.
View Article : Google Scholar : PubMed/NCBI
|
